EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

An interview with: John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston TX And with: Jayesh Desai MD, Medical Oncologist, Associate Director Clinical Research, Peter MacCallum Cancer Centre, Melbourne, Australia, Co-Chair, AACR Clinical Committee. CHICAGO, USA—A safer way of targeting tumors with mutated human epidermal growth factor receptor 2 (HER2) in patients with previously treated non-small cell lung cancer was discussed at the 2025 Annual Meeting of the American Association for Cancer Research, in Chicago. Promising clinical benefits were reported from the Beamion LUNG-1 trial, in which patients were treated with the anti-HER2 tyrosine kinase inhibitor zongertinib that doesn’t affect the epidermal growth factor receptor (EGFR). Audio Journal of Oncology correspondent Peter Goodwin met up with the study’s presenting author John V Heymach MD PhD, Chair of Thoracic/Head and Neck Medical Oncology, at the University of Texas MD Anderson Cancer Center in Houston, and with Jayesh Desai MD, Medical Oncologist at the Peter McCallum Cancer Centre in Melbourne Australia, Co-Chair of the AACR Clinical Committee, who moderated a press briefing held to discuss the findings of the Beamion LUNG-1 study.

There are no comments yet.

Please log in to write the first comment.